Asia
The investment made to build this end-to-end cell culture biopharmaceutical contract development and manufacturing organization facility clocked in at approximately $2 billion.
Merck and Eisai announced that their combination of Merck’s checkpoint inhibitor Keytruda and Eisai’s Lenvima, a tyrosine kinase inhibitor, significantly improved progression-free survival in advanced endometrial cancer.
The results published in the NEJM state that pegcetacoplan met the study’s primary endpoint for efficacy, demonstrating an advantage over eculizumab with a statistically significant improvement in adjusted means of 3.8 g/dL of hemoglobin at week 16 (p<0.001). An impressive 85% of patients were transfusion free at 16 weeks, in contrast to only 15% of eculizumab-treated patients.
European genetic studies aren’t particularly accurate when applied to Middle East populations, according to new research from the Qatar Foundation.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Anima Biotech’s strategic collaboration with Takeda Pharmaceutical, just announced today, uses its novel platform for discovery of mRNA translation modulators to discover and develop a new class of therapies for neurological diseases.
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
With more European countries pausing dosing of AstraZeneca’s COVID-19 vaccine over concerns about potential blood clotting side effects, Russia is seeking to fill in the gaps with its Sputnik V vaccine.
Nearly five years to the day after striking the deal, AVEO Oncology and CANbridge Life Sciences announce the termination of their collaboration and licensing agreement for AVEO’s AV-203.
The Japanese pharma giant is aiming for double-digit revenue growth of its Growth and Emerging Markets Business Unit (GEM BU) by 2030. Here’s how they plan to do it.
PRESS RELEASES